Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Frequency Therapeutics Inc.

www.frequencytx.com

Latest From Frequency Therapeutics Inc.

IPO Update: 35 Biopharmas Provide -6.1% Average Return; New Offerings Feel Stock Market Impact

Only 16 drug developers that went public in the US during the first three quarters are trading in positive territory. While the IPO queue keeps growing, ADC Therapeutics and Monopar cite "market conditions" as they postpone their offerings.

Financing Business Strategies

Finance Watch: SpringWorks, Satsuma Launch IPOs; BioNTech Filing Shows US-China Trade War Impact

BioNTech has plenty of cash and is gearing up for an IPO, but money from a Hong Kong investor is in limbo. Plus, Satsuma and SpringWorks bring US IPO total to 34 this year, Fate's FOPO raises $150.5m and Pharvaris brings in $66m.

Financing Business Strategies

Venture Funding Deals: July Sees Seven Rounds Of $100m Or More

Century Therapeutics brings in $250m for its cell therapy programs in a series A round, while immunotherapy specialist BioNTech sets a record for series B, raising $350m. Another five firms brought in rounds of $100m or greater...

Deals Financing

Finance Watch: Cell And Gene Therapy Fundraising Down Overall In Q2, But VC Deals Still Soared

Private Company Edition: ARM's Q2 report shows a 38% decline in financings, but venture capital and upfront fees from deals were robust. Also, Servier raises $405m in the US, Frequency closes a $62m series C and VenatoRx accesses US government cash.

Financing Regenerative Medicine
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Otolaryngology
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Frequency Therapeutics Inc.
  • Senior Management
  • David Lucchino, Pres. & CEO
    Chris Loose, PhD, CSO
    Dana C Hilt, MD, CMO
    Carl Lebel, PhD, Chief Dev. Officer
    Ajay Rai, VP, Bus. Dev.
  • Contact Info
  • Frequency Therapeutics Inc.
    Phone: (866) 389-1970
    19 Presidential Way
    Woburn, MA 01801
    USA
UsernamePublicRestriction

Register